Blake Borgeson
CIK: 0001856094
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
RECURSION PHARMACEUTICALS, INC.
Discretionary Trading P&L
Holdings
Transaction History (21 total)
- Oct 6, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct50K shares at avg. $4.84$242K - Sep 1, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct30K shares at avg. $3.34$100K - Aug 4, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct30K shares at avg. $3.25$98K - Jul 7, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct40K shares at avg. $3.96$159K - Jun 17, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct88.4K shares- - Jun 2, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct30K shares at avg. $3.68$110K - May 5, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct30K shares at avg. $3.52$106K - Apr 7, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct30K shares at avg. $3.10$93K - Mar 3, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct170K shares at avg. $3.46$588K - Feb 3, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct220K shares at avg. $4.20$924K - Jan 6, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct220K shares at avg. $4.36$959K - Dec 2, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct220K shares at avg. $4.37$961K - Jun 18, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct22K shares- - Jan 2, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct1.7K shares- - Nov 12, 2024RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct11.4K shares at avg. $7.64$87K - Oct 29, 2024RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct11.4K shares at avg. $6.72$77K - Oct 15, 2024RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct11.4K shares at avg. $6.67$76K - Oct 1, 2024RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct2K shares- - Oct 1, 2024RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct11.4K shares at avg. $6.22$71K - Sep 17, 2024RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct11.4K shares at avg. $6.84$78K - Sep 3, 2024RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct11.4K shares at avg. $6.27$72K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 6, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 50,000 | $4.84 | $242,000 | Direct |
| Sep 1, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 30,000 | $3.34 | $100,200 | Direct |
| Aug 4, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 30,000 | $3.25 | $97,500 | Direct |
| Jul 7, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 40,000 | $3.96 | $158,500 | Direct |
| Jun 17, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 88,424 | - | $0 | Direct |
| Jun 2, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 30,000 | $3.68 | $110,400 | Direct |
| May 5, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 30,000 | $3.52 | $105,600 | Direct |
| Apr 7, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 30,000 | $3.10 | $93,000 | Direct |
| Mar 3, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 170,000 | $3.46 | $588,200 | Direct |
| Feb 3, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 220,000 | $4.20 | $924,000 | Direct |
| Jan 6, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 220,000 | $4.36 | $959,200 | Direct |
| Dec 2, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 220,000 | $4.37 | $961,400 | Direct |
| Jun 18, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 22,016 | - | - | Direct |
| Jan 2, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 1,734 | - | $0 | Direct |
| Nov 12, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 11,447 | $7.64 | $87,457 | Direct |
| Oct 29, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 11,447 | $6.72 | $76,926 | Direct |
| Oct 15, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 11,447 | $6.67 | $76,326 | Direct |
| Oct 1, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 2,026 | - | $0 | Direct |
| Oct 1, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 11,447 | $6.22 | $71,150 | Direct |
| Sep 17, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 11,447 | $6.84 | $78,333 | Direct |
| Sep 3, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 11,447 | $6.27 | $71,718 | Direct |
1-21 of 21 transactions
About Borgeson Blake
Borgeson Blake (SEC CIK 0001856094) files insider reports with the SEC as Director of RECURSION PHARMACEUTICALS, INC. (RXRX).
Signal8 holds 21 ownership filings by Borgeson Blake, all Form 4s, filed between Sep 5, 2024 and Oct 7, 2026. Those filings report 21 transactions, from Sep 3, 2024 to Oct 6, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Borgeson Blake's filings is in SALT LAKE CITY, UT.
Recent filings by Borgeson Blake
- Oct 6, 2026: Open-market sale of RXRX shares (Form 4, code S).
- Sep 1, 2026: Open-market sale of RXRX shares (Form 4, code S).
- Aug 4, 2026: Open-market sale of RXRX shares (Form 4, code S).
- Jul 7, 2026: Open-market sale of RXRX shares (Form 4, code S).
- Jun 17, 2026: Grant or award of RXRX shares (Form 4, code A).
Other insiders filing for RECURSION PHARMACEUTICALS, INC. (RXRX)
- HERSHBERG ROBERT, Director
- Dar Zavain, Director
- Li Dean Y, Director
- Taylor Ben R, Chief Financial Officer
- Khan Najat, CEO and President
- Hallett David, Chief Scientific Officer